KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Gains from Sales and Divestitures (2018 - 2022)

Historic Gains from Sales and Divestitures for Vir Biotechnology (VIR) over the last 5 years, with Q4 2022 value amounting to $349496.0.

  • Vir Biotechnology's Gains from Sales and Divestitures rose 29154.39% to $349496.0 in Q4 2022 from the same period last year, while for Dec 2022 it was $349496.0, marking a year-over-year increase of 29154.39%. This contributed to the annual value of $349496.0 for FY2022, which is 29154.39% up from last year.
  • Vir Biotechnology's Gains from Sales and Divestitures amounted to $349496.0 in Q4 2022, which was up 29154.39% from $216886.0 recorded in Q1 2022.
  • In the past 5 years, Vir Biotechnology's Gains from Sales and Divestitures registered a high of $2.2 million during Q4 2018, and its lowest value of $52963.0 during Q1 2021.
  • Moreover, its 5-year median value for Gains from Sales and Divestitures was $483787.5 (2020), whereas its average is $906979.1.
  • Per our database at Business Quant, Vir Biotechnology's Gains from Sales and Divestitures crashed by 9501.86% in 2021 and then soared by 30950.47% in 2022.
  • Over the past 5 years, Vir Biotechnology's Gains from Sales and Divestitures (Quarter) stood at $2.2 million in 2018, then decreased by 11.63% to $2.0 million in 2019, then dropped by 9.79% to $1.8 million in 2020, then tumbled by 95.02% to $89261.0 in 2021, then surged by 291.54% to $349496.0 in 2022.
  • Its Gains from Sales and Divestitures stands at $349496.0 for Q4 2022, versus $216886.0 for Q1 2022 and $89261.0 for Q4 2021.